现在位置 >首页 > dubin98发表的所有文章
dubin98 ⁄ 发表于1年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: ARDS的机械能:与Gattinoni手拉手已关闭评论
Mechanical Power in ARDS: Hand in Hand With Gattinoni ICU Management & Practice, Volume 25 - Issue 2, 2025 PRINT OPTIM......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [Intensive Care Med发表论文]:坏死性胰腺炎及早期持续器官功能衰竭患者的早期与延迟导管引流已关闭评论
Early versus delayed catheter drainage for patients with necrotizing pancreatitis and early persistent organ failure (TIMING): a mult......
dubin98 ⁄ 发表于1年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: 采用人工智能预测感染性休克患者的ICU病死率已关闭评论
Predicting Septic Shock Mortality in ICUs with AI  In Sepsis Sun, 4 May 2025 Septic shock, a severe manifest......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ Intensive Care Medicine在线免费阅读已关闭评论
ONLINE FIRST (FREE ACCESS) STANDARD OF CARE IN THE INTENSIVE CARE UNIT OPEN ACCESS ~ What's New in Intensive Care Renal repl......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA Netw Open发表论文]:应用电子病历减少再入院风险已关闭评论
Original Investigation  Health Informatics Electronic Health Record Interventions to Reduce Risk of Hospital Readmissions:......
dubin98 ⁄ 发表于1年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: 休克治疗中的少即是多已关闭评论
Less is More in Shock Management In ICU Tue, 6 May 2025 Permissive hypotension, phenotyping shock, vasopressor select......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA发表论文]:初始抗生素选择策略与后续的抗生素使用已关闭评论
Research Letter  Initial Antibiotic Selection Strategy and Subsequent Antibiotic Use—Insights From the INSPIRE Trials Shru......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [Chest发表论文]:感染性休克患者应用大剂量维生素B12已关闭评论
Critical Care: Research Letters Use of High-Dose Hydroxocobalamin for Septic Shock Jason R. Carr, Brian Locke, Jayshil J. Patel......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA Netw Open发表论文]:流感疾病负担估计以及流感疫苗的直接和间接获益已关闭评论
Original Investigation  Infectious Diseases Estimated Burden of Influenza and Direct and Indirect Benefits of Influenza Va......
dubin98 ⁄ 发表于1年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA Intern Med发表论文]:肿瘤Me-Too药物与原研药在随机临床试验中的比较已关闭评论
Research Letter  Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials Timothée Olivier,......
×
腾讯微博